BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26450587)

  • 1. c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.
    Luo H; Chen Z; Wang S; Zhang R; Qiu W; Zhao L; Peng C; Xu R; Chen W; Wang HW; Chen Y; Yang J; Zhang X; Zhang S; Chen D; Wu W; Zhao C; Cheng G; Jiang T; Lu D; You Y; Liu N; Wang H
    Brain; 2015 Dec; 138(Pt 12):3654-72. PubMed ID: 26450587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into acquired temozolomide resistance in glioblastoma?
    Happold C; Weller M
    Brain; 2015 Dec; 138(Pt 12):3468-70. PubMed ID: 26598490
    [No Abstract]   [Full Text] [Related]  

  • 3. The Error-Prone DNA Polymerase κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling.
    Peng C; Chen Z; Wang S; Wang HW; Qiu W; Zhao L; Xu R; Luo H; Chen Y; Chen D; You Y; Liu N; Wang H
    Cancer Res; 2016 Apr; 76(8):2340-53. PubMed ID: 26960975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
    Tian T; Mingyi M; Qiu X; Qiu Y
    Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
    Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
    Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
    Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P
    Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA-XIST interacts with
    Du P; Zhao H; Peng R; Liu Q; Yuan J; Peng G; Liao Y
    Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28831025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.
    Cheng ZX; Yin WB; Wang ZY
    Int J Mol Med; 2017 Nov; 40(5):1307-1314. PubMed ID: 28901390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
    Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
    Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely.
    Xiao S; Yang Z; Qiu X; Lv R; Liu J; Wu M; Liao Y; Liu Q
    Oncotarget; 2016 Aug; 7(31):50229-50238. PubMed ID: 27384876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
    Lan F; Pan Q; Yu H; Yue X
    J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs.
    Roos WP; Tsaalbi-Shtylik A; Tsaryk R; Güvercin F; de Wind N; Kaina B
    Mol Pharmacol; 2009 Oct; 76(4):927-34. PubMed ID: 19641035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
    Chen Y; Li R; Pan M; Shi Z; Yan W; Liu N; You Y; Zhang J; Wang X
    J Neurooncol; 2017 Jul; 133(3):477-485. PubMed ID: 28501897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.
    Ge X; Pan MH; Wang L; Li W; Jiang C; He J; Abouzid K; Liu LZ; Shi Z; Jiang BH
    Cell Death Dis; 2018 Nov; 9(11):1128. PubMed ID: 30425242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
    Gao YT; Chen XB; Liu HL
    Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
    Gil Del Alcazar CR; Todorova PK; Habib AA; Mukherjee B; Burma S
    Mol Cancer Res; 2016 Oct; 14(10):928-940. PubMed ID: 27358111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
    Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
    Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
    Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
    Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.